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A Responsible Approach
To the Editor: A recent paper1 in The Journal aptly
described the challenges inherent in using genomic pro-
ﬁles to predict risk for common diseases and to develop
personalized risk-prevention advice. Companies or other
organizations that take a responsible approach to these
challenges can potentially offer new opportunities for
disease prevention, early detection, and treatment.
The authors took a sample of the loci covered by the tests
of seven companies in the ﬁeld and have shown that most
of these loci do not pass simple quality criteria. The chal-
lenge with the authors’ analysis is that it analyzes the
pool of loci used by all seven companies, instead of break-
ing the analysis down by company or organization; hence,
the approach does not distinguish between organizations
that take a rigorous and responsible approach to the eval-
uation of risk and organizations that base the risk assess-
ment on unreliable scientiﬁc information.
We share the authors’ concerns about companies that
report genetic risk based on a single association study or
on studies with methodological weaknesses. However, we
strongly believe that customers can beneﬁt from a person-
alized report of those genetic associations found in ge-
nome-wide-association studies that were replicated inmul-
tiple populations with sound epidemiological, statistical,
and laboratory practices. Many examples of reliable, repli-
cated associations have been reported, including between
transcription factor TCF7L2 (MIM 602228) and diabetes
and between NOD2 (MIM 605956) and Crohn’s disease.2
Taking a responsible approach means that companies
utilize only high-quality association studies to bring cus-
tomers accurate genetic risk predictions, as well as effective
strategies for reducing risk for those genetic conditions to
which they are predisposed. In addition to using rigorous
and transparent scientiﬁc standards for inclusion in the130 The American Journal of Human Genetics 83, 127–147, July 200testing panel, a responsible approach is to provide cus-
tomers and their doctors with resources such as genetic
counselors, physician expertise, and epidemiologists. By
taking a responsible approach, the personalized genomics
community can work together with individuals and their
medical providers to enable people to live longer, healthier
lives.
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Web Resources
The URL for data presented herein is as follows:
Online Mendelian Inheritance in Man (OMIM), http://
www.ncbi.nlm.nih.gov/Omim/
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